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Abstract
Background:Volasertib inducesmitotic arrest and apoptosis by targeting Polo-like kinases. In this
phase I dose-escalation study, the maximum tolerated dose (MTD), pharmacokinetics (PK), and
preliminary efficacy of volasertib were determined in pediatric patients.
Methods: Patients aged 2 to <18 years with relapsed/refractory acute leukemia/advanced
solid tumors (ST) without available effective treatments were enrolled—cohort C1 (aged 2 to
<12 years); cohort C2 (aged 12 to <18 years). The patients received volasertib intravenously
(starting dose: 200 mg/m2 body surface area on day 1, every 14 days). The primary endpoint was
the pediatricMTD for further development.
Results: Twenty-two patients received treatment (C1: leukemia, n = 4; ST, n = 8; C2: leukemia,
n = 3; ST, n = 7). No dose-limiting toxicities (DLTs) occurred up to 300 mg/m2 volasertib in C1;
Abbreviations: AEs, adverse events; ALL, acute lymphoblastic leukemia; AML, acutemyeloid leukemia; AUC0-∞,norm, dose-normalized area under the curve from time 0 extrapolated to infinity;
Cmax,norm, dose-normalizedmaximum plasma concentration; CNS, central nervous system; CTCAE, Common Terminology Criteria for Adverse Events; DLT, dose-limiting toxicity; DMC, data
monitoring committee; EFS, event-free survival; IC50, the half maximal inhibitory concentration;MTD, maximum tolerated dose; OR, overall response; OS, overall survival; PD, progressive
disease; PFS, progression-free survival; PK, pharmacokinetics; PLK1, Polo-like kinase 1; QT, uncorrectedQT interval; QTcF, correctedQT interval by Fridericia’s correction of formula; SD, stable
disease; ST, solid tumors.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
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two patients in C2, at 250mg/m2 volasertib, had DLTs in cycle 1, one of which led to death; there-
fore, theMTDof volasertib in C2was 200mg/m2. Themost common grade 3/4 adverse events (all
patients) were febrile neutropenia, thrombocytopenia, and neutropenia (41% each). Stable dis-
ease (SD)was the best objective response (leukemia, n= 5; ST, n= 2); the duration of SDwas short
in all patients, except in onewith an ST. PK profiles were generally comparable across dose groups
andwere consistent with those in adults.
Conclusion:ThepediatricMTD/dose for further developmentwas identified. Therewerenounex-
pected safety or PK findings; limited antitumor/antileukemic activity was demonstrated.
K EYWORDS
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1 INTRODUCTION
Approximately 1 in 285 children and adolescents will be diagnosed
with cancer before they are 20 years old.1 Over the last 50 years,
treatment advances have increased the overall 5-year survival rate for
childhood cancers to approximately 80%.1,2 However, cancer is still the
leading disease-related cause of death in those aged ≤19 years.3 Mor-
tality rates in pediatric patients with cancer are partially driven by the
negative health impact of the intensive chemotherapy regimens nec-
essary for effectively treating some cancers. These regimens can lead
to acute morbidity and mortality, or cause significant long-term side
effects that prevent therapy intensification andnegatively affect treat-
ment outcomes; survivors’ quality of life may also be impaired.2,4 As
such, agents with innovative mechanisms of action and molecular tar-
gets, which provide improved clinical efficacy and favorable safety pro-
files, are urgently needed.
One such target is Polo-like kinase 1 (PLK1), a serine/threonine
kinase that is active in several key stages of mitosis,5 and—when
dysregulated—may play a role in promoting carcinogenesis and malig-
nant transformation.6 High PLK1 expression has been observed in sev-
eral human cancers and has been correlated with a poor prognosis.7
Inhibition of PLK1 can cause cell-cycle arrest and apoptosis, prefer-
entially in cancer cells over normal diploid or nondividing cells.6,8–14
These data provide a strong rationale for targeting PLK1 with novel
anticancer therapies.15
Volasertib is a small-molecule, ATP-competitive kinase inhibitor
that potently and specifically inhibits PLK1 and two closely related
kinases, PLK2 and PLK3 (with half maximal inhibitory concentration
[IC50] values of 0.87, 5, and 56 nmol/L, respectively).
16 Volasertib
has an antimitotic mechanism of action, inhibiting cell proliferation
via perturbation of spindle assembly, which leads to prometaphase
cell-cycle arrest and subsequent apoptosis.16 Preclinically, volasertib
has shown antiproliferative effects in various cancer cell lines, along-
side in vivo activity in multiple xenograft models.16,17 Phase I and II
clinical trials have determined the maximum tolerated dose (MTD) of
volasertib, and evaluated its pharmacokinetics (PK), safety, and effi-
cacy in adults with acute myeloid leukemia (AML) or solid tumors (ST).
TheMTDof volasertibmonotherapy in adultswith relapsed/refractory
AML was 450 mg every 2 weeks. The most common adverse events
(AEs)were cytopenia and related complications,with febrile neutrope-
nia and infections being among the most common grade ≥3 AEs.18 In
adults with ST, the MTD was 400 mg every 3 weeks (Q3W); based
on additional safety results, 300 mg Q3W was chosen as the recom-
mended dose for further phase II development. Most AEs were hema-
tologic and included anemia, neutropenia, and thrombocytopenia.19 In
a phase I dose-escalation trial, volasertib monotherapy demonstrated
favorable PK and preliminary antitumor activity in adult patients with
advanced ST.15 However, the lack of convincing evidence of effi-
cacy with monotherapy in unselected adult populations with ST in
phase II trials led to discontinuation of volasertib development in this
indication.20–22 In a phase II trial in adult patients with previously
untreatedAML, volasertib combinedwith low-dose cytarabine (LDAC)
achieved a higher response rate and improved event-free survival
(EFS) compared to that achieved with LDAC monotherapy.23 There
have been promising preclinical data in childhood tumormodels, which
indicate volasertib monotherapy may have clinical benefit in pediatric
ST.8,24–27 This phase I study was conducted to identify theMTD or the
relevant pediatric dose for further development of volasertib, along-
side its safety, PK/pharmacodynamics, and efficacy in children with
either relapsed/refractory acute leukemia or advanced ST, for whom
no effective treatment was available.
2 METHODS
2.1 Patients
This multinational, multisite, open-label, noncontrolled, phase I
dose-escalation trial enrolled patients aged 2 to <18 years with
either relapsed/refractory acute leukemia after at least two previous
intensive treatment regimens, or advanced ST, including lymphomas,
for whom there was no known effective treatment at the time of
trial entry. Patients were included if they had a Lansky score >60 (2
to <12 years age group) or Karnofsky score >60 (12 to <18 years
age group), and a life expectancy of more than 6 weeks as judged by
the investigator. Parents or legal guardians of the enrolled patients
providedwritten informed consent; thiswas obtained from the patient
whenever feasible.
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Key exclusion criteria included Down syndrome, or the presence
of symptomatic central nervous system (CNS) tumors, left ventricular
shortening fraction by echocardiography<30%, and clinically relevant
QT interval (QTcF; corrected QT interval by Fridericia’s correction for-
mula) prolongation. The study was conducted in accordance with the
principles of the Declaration of Helsinki, the International Council for
Harmonisation Guideline for Good Clinical Practice, and local legisla-
tion. The trial, approved by the ethical committee/institutional review
board of the participating institutions, was registered at ClinicalTri-
als.gov (NCT01971476).
2.2 Study design and endpoints
The primary endpoint was the pediatric MTD of volasertib, based on
dose-limiting toxicities (DLTs) occurring in the first treatment cycle
(cycle 1). If theMTDwas not reached due to early signals of activity or
tolerability issues, then the recommended pediatric dose of volasertib
appropriate for further development was defined, based on the rec-
ommendations of an appointed external independent data monitor-
ing committee (DMC). The MTD was defined as the highest dose at
which no more than one out of six patients experienced DLTs during
cycle 1.
Dose escalations were performed separately in two age groups
of at least six evaluable patients (aged 2 to <12 years and 12 to
<18 years) and proceeded via a standard “3 + 3” design. The DMC
was responsible for the overall safety of the treated patients and
for providing recommendations on dose escalation and de-escalation.
Volasertib was administered as a single dose (intravenous infusion
over ∼1 h) on day 1 of each 14-day cycle. The starting dose was 200
mg/m2 body surface area on day 1, and the dose was either escalated
or de-escalated in steps of up to 50 mg/m2 at each administration.
Treatment cycles were repeated, until progressive disease (PD), drug-
related AEs without recovery to predose grades (graded according
to the National Cancer Institute’s Common Terminology Criteria for
Adverse Events [CTCAE] version 3.0), or other reasons for discontin-
uation. Secondary endpoints included the overall safety of volasertib,
tolerability and PK outcomes, best overall response (OR), antileukemia
activity, EFS/progression-free survival (PFS), overall survival (OS), and
pharmacodynamics.
Patients could receive supportive care, including blood products,
anti-infectious agents and analgesics, and growth factors such as gran-
ulocyte colony stimulating factor, according to local guidelines.
2.3 Safety analysis
DLTs were defined as any drug-related CTCAE grade ≥3 AEs. Excep-
tions were reduced blood cell count (any grade) without associated
clinical complications qualifying for DLT; febrile neutropenia (grade
3); infection (grade 3) with neutrophil count <1000 mm3; elevated
uric acid (grade 3); and nausea, vomiting, and/or diarrhea managed
by adequate therapy (ie, recovery to grade ≤2). The first DLT analy-
sis focused on MTD determination during the first treatment course
only; a second analysis of DLTs during all courses provided support for
determination of the MTD. The MTDwas determined using data from
all patients who received treatment during the dose-escalation/de-
escalation phase. Following recovery from a DLT, therapy could be
continued at a reduced dose. Analyses of overall safety and tolera-
bility focused on the incidence and severity of AEs, the number of
patients with clinically relevant laboratory value changes, and the
number of patients with cardiac activity changes (prolonged QTcF
interval).
2.4 Efficacy analysis
Efficacy in patients with acute leukemia was assessed via bone mar-
row evaluation at the end of cycle 2, or earlier if PD was suspected;
further bone marrow samples could be taken at the investigator’s dis-
cretion. The best ORs were determined as described previously.23,28
Assessmentof efficacy inpatientswithSTwasplannedafter four treat-
ment cycles, and at the time of progression using tumormeasurements
and evaluation according to the Response Evaluation Criteria in Solid
Tumors version 1.1.29
2.5 PK analysis
Plasma concentrations of volasertib were determined by a validated
high-performance liquid chromatography-tandem mass spectrometry
assay. For quantification of plasma concentrations, 2 mL blood was
taken as follows: immediately before volasertib administration; imme-
diately after the end of the infusion; and at five additional time points
in cycle 1: 1:20-1:40 h, 2:00-4:00 h, 24:00 h (± 4), 96:00 h (± 48), and
216:00 h (± 48) after the start of infusion. The following PK param-
eters were calculated by noncompartmental analysis and evaluated
as secondary endpoints: dose-normalized area under the curve from
time 0 extrapolated to infinity (AUC0-∞,norm); dose-normalized maxi-
mum plasma concentration (Cmax,norm); plasma half-life (t1/2); plasma
clearance rate (CL); steady-state volumeof distribution (Vss); andmean
residence time.
2.6 Pharmacodynamic analysis
Pharmacodynamic endpoints included changes in neutrophil and
platelet cell counts, QTcF prolongation, and reduction of leukemia
blast cell count in peripheral blood (patients with leukemia only) after
volasertib administration.
2.7 Statistical analysis
All analyses were descriptive and exploratory in nature. Patients
receiving at least one dose of the study drug (the treated set) were
included in the primary endpoint analysis. Patients who had not com-
pleted at least one cycle for reasons other than DLT were replaced in
order to determine the MTD, but were included in the treated set for
all other analyses.
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TABLE 1 Baseline patient characteristics
Age 2 to<12 years Age 12 to<18 years
Volasertib dose (mg/m2) 200 250 300 Total 200 250 Total
Number of patients, n (%) 3 (100.0) 3 (100.0) 6 (100.0) 12 (100.0) 6 (100.0) 4 (100.0) 10 (100.0)
Median age, years (range) 8.0 (3-10) 7.0 (3-9) 7.0 (2-11) 7.5 (2-11) 14.0 (12-17) 16.0 (14-17) 15.0 (12-17)
Male, n (%) 2 (66.7) 1 (33.3) 3 (50.0) 6 (50.0) 4 (66.7) 4 (100.0) 8 (80.0)
Median performance statusa
(range)
90.0 (70-90) 90.0 (80-100) 95.0 (70-100) 90.0 (70-100) 90.0 (80-100) 90.0 (70-100) 90.0 (70-100)
Cancer type, n (%)
Acute leukemiab 2 (66.7) 2 (66.7) 0 4 (33.3) 2 (33.3) 1 (25.0) 3 (30.0)
ALL 2 (66.7) 1 (33.3) 0 3 (25.0) 1 (16.7) 1 (25.0) 2 (20.0)
AML 0 1 (33.3) 0 1 (8.3) 1 (16.7) 0 1 (10.0)
Solid tumor 1 (33.3) 1 (33.3) 6 (100.0) 8 (66.7) 4 (66.7) 3 (75.0) 7 (70.0)
Renal 0 0 1 (16.7) 1 (8.3) 2 (33.3) 0 2 (20.0)
Liver 0 0 1 (16.7) 1 (8.3) 0 0 0
Neuroblastoma 0 0 0 0 1 (16.7) 0 1 (10.0)
Bonec 0 0 2 (33.3) 2 (16.7) 0 2 (50.0) 2 (20.0)
Soft tissue 1 (33.3) 1 (33.3) 1 (16.7) 3 (25.0) 1 (16.7) 0 1 (10.0)
Otherd 0 0 1 (16.7) 1 (8.3) 0 1 (25.0) 1 (10.0)
Previous treatment, n (%)
Systemic anti-solid-tumor
chemotherapies
1 (33.3) 1 (33.3) 6 (100.0) 8 (66.7) 4 (66.7) 3 (75.0) 7 (70.0)
Radiotherapy 1 (33.3) 1 (33.3) 5 (83.3) 7 (58.3) 5 (83.3) 2 (50.0) 7 (70.0)
Surgeries 1 (33.3) 0 6 (100.0) 7 (58.3) 4 (66.7) 3 (75.0) 7 (70.0)
Systemic antileukemia
chemotherapies
2 (66.7) 2 (66.7) 0 4 (33.3) 2 (33.3) 1 (25.0) 3 (30.0)
Stem cell transplantations 2 (66.7) 2 (66.7) 0 4 (33.3) 4 (66.7) 2 (50.0) 6 (60.0)
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acutemyeloid leukemia.
aLansky score (age 2 to<12 years) or Karnofsky score (age 12 to<18 years).
bAll patients with leukemia failed chemotherapy and allogeneic stem cell transplantation prior to enrolment into this trial.
cEwing sarcoma (n= 1, age 12 to<18 years); osteosarcomas (n= 2, age 2 to<12 years; n= 1, age 12 to<18 years).
dDesmoplastic small round cell tumors (n= 2).
3 RESULTS
3.1 Patients and treatment
Between October 2013 and March 2016, 22 patients were enrolled
and received at least one cycle of volasertib; these included12patients
in the 2 to <12 years age group (acute leukemia, n = 4; ST, n = 8) and
10 patients in the 12 to <18 years age group (acute leukemia, n = 3;
ST, n = 7). Patient baseline characteristics are shown in Table 1. The
median agewas 7.5 years (range: 2-11) in the 2 to<12 years age group
and 15.0 years (range: 12-17) in the 12 to <18 years age group; all
patients had previously received systemic chemotherapy. Overall,
seven patients had acute leukemia (acute lymphoblastic leukemia
[ALL], n= 5; AML, n= 2) and 15 patients had ST. At data cut-off (March
31, 2016), all 22 patients had discontinued treatment, mostly due to
PD (2 to <12 years, 91.7%; 12 to <18 years, 80.0%), and all seven
patients with leukemia and 13/15 patients with ST had died.
In the 2 to <12 years age group, three patients received volasertib
at a dose of 200 mg/m2, three at 250 mg/m2, and six at 300 mg/m2
(Table 1). In the 12 to <18 years age group, six patients were treated
with a volasertib dose of 200 mg/m2 and four received 250 mg/m2.
The median treatment duration in the 2 to <12 years age group was
22.0 days (range: 15-71), andwas longer in patientswith leukemia than
in patients with ST (37.5 days [range: 29-71] vs 15.0 days [range: 15-
36]). In the 12 to <18 years age group, the median treatment duration
was 15.0 days (range: 15-484), and did not differ by cancer type.
3.2 DLTs andMTD
In patients aged 2 to <12 years, no DLTs were observed in any treat-
ment cycle at volasertib doses of 200, 250, or 300 mg/m2. Therefore,
the DMC recommended that sufficient safety data had been collected
for volasertib 300 mg/m2 with no efficacy demonstrated that justified
exposing additional patients to volasertibmonotherapy; consequently,
there were no dose escalations beyond 300mg/m2.
In patients aged12 to<18years, twopatients treated at 250mg/m2
experienced six DLTs in cycle 1. These were intracranial hemorrhage
(grade 5) in a patient with ALL (progressive leukemia had occurred in
the CNS) and a platelet count of 24 × 109/L; and anemia (grade 4),
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TABLE 2 Adverse eventsa occurring in>15% of patients in either age group by system organ class
Age 2 to<12 years
n= 12
Age 12 to<18 years
n= 10
System organ class
Preferred term
All
grades G3 G4
All
grades G3 G4
Blood disorders 9 (75) 0 8 (67) 8 (80) 3 (30) 5 (50)
Anemia 6 (50) 3 (25) 1 (8) 4 (40) 2 (20) 1 (10)
Febrile neutropenia 5 (42) 5 (42) 0 4 (40) 3 (30) 1 (10)
Thrombocytopenia 4 (33) 0 4 (33) 5 (50) 1 (10) 4 (40)
Neutropenia 5 (42) 0 5 (42) 4 (40) 0 4 (40)
Leukopenia 2 (17) 0 2 (17) 2 (20) 0 2 (20)
Gastrointestinal disorders 6 (50) 0 0 7 (70) 3 (30) 0
Vomiting 3 (25) 0 0 6 (60) 1 (10) 0
Nausea 2 (17) 0 0 5 (50) 1 (10) 0
Abdominal pain 3 (25) 0 0 3 (30) 0 0
Diarrhea 2 (17) 0 0 1 (10) 0 0
Constipation 0 0 0 2 (20) 0 0
General disorders/
administration-site conditions
6 (50) 2 (17) 0 7 (70) 2 (20) 0
Pyrexia 2 (17) 0 0 3 (30) 1 (10) 0
Fatigue 2 (17) 0 0 3 (30) 0 0
Chest pain 0 0 0 2 (20) 0 0
Asthenia 1 (8) 1 (8) 0 2 (20) 1 (10) 0
Musculoskeletal and connective
tissue disorders
0 0 0 5 (50) 1 (10) 0
Myalgia 0 0 0 2 (20) 0 0
Arthralgia 0 0 0 2 (20) 0 0
Nervous system disordersb 3 (25) 0 0 5 (50) 0 1 (10)
Headache 1 (8) 0 0 4 (40) 1 (10) 0
Investigations 5 (42) 0 2 (17) 5 (50) 3 (30) 2 (20)
WBC count decreased 2 (17) 1 (8) 1 (8) 2 (20) 0 2 (20)
Platelet count decreased 2 (17) 0 1 (8) 2 (20) 0 1 (10)
ALT/AST increased 2 (17) 0 0 2 (20) 0 0
Blood creatinine increased 2 (17) 0 0 1 (10) 1 (10) 0
Lymphocyte count decreased 2 (17) 1 (8) 0 2 (20) 0 0
Neutrophil count decreased 1 (8) 0 1 (8) 2 (20) 0 2 (20)
Blood phosphorus decreased 0 0 0 2 (20) 1 (10) 0
ElectrocardiogramQT prolonged 1 (8) 0 0 2 (20) 1 (10) 0
Metabolism and nutrition disorders 4 (33) 2 (17) 0 4 (40) 1 (10) 0
Hyponatremia 2 (17) 0 0 2 (20) 1 (10) 0
Decreased appetite 3 (25) 0 0 0 0 0
Hyperglycemia 1 (8) 0 0 2 (20) 0 0
Hypercalcemia 1 (8) 0 0 2 (20) 0 0
Neoplasms benign, malignant, and
unspecified
3 (25) 1 (8) 0 1 (10)c 0 0
Malignant neoplasm progression 2 (17)c 0 0 1 (10) 0 0
Respiratory, thoracic, and
mediastinal disorders
4 (33) 0 1 (8) 3 (30) 0 1 (10)
Epistaxis 0 0 0 2 (20) 0 0
(Continues)
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TABLE 2 (Continued)
Age 2 to<12 years
n= 12
Age 12 to<18 years
n= 10
System organ class
Preferred term
All
grades G3 G4
All
grades G3 G4
Skin and subcutaneous tissue
disorders
5 (42) 0 0 3 (30) 0 0
Pruritus 1 (8) 0 0 2 (20) 0 0
Abbreviations: AEs, adverse events; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTCAE, Common Terminology Criteria for Adverse
Events; G, grade; QT, uncorrectedQT interval;WBC, white blood cell.
Note. The worst CTCAE grade AEs are listed independently for system organ class and preferred term; all observed AEs are listed for the preferred term,
while only the AE of the highest grade for each patient is listed for the system organ class.
aAEs by treatment, worst CTCAE grade, system organ class, and preferred team are listed.
bIn the 2 to <12 year age group, this includes cranial nerve disorder, headache, and dysesthesia (each n = 1). In the 12 to <18 year age group, this includes
intracranial hemorrhage, paresthesia, third nerve disorder, paraplegia, and peripheral sensory neuropathy (each n= 1) and headache (n= 4).
cAll events were grade 5.
febrile neutropenia (grade 4), thrombocytopenia (grade 4), leukopenia
(grade4), gastrointestinal hemorrhage (grade3), andasthenia (grade3)
in a patient with osteosarcoma. Therefore, in patients aged 12 to <18
years, the MTD of volasertib was 200 mg/m2. Additional DLTs were
observed in later treatment cycles—QTcFprolongationoccurred inone
patient with leukemia treated at 200 mg/m2 (grade 3, cycle 6), and in
one patient with an ST treated at 250mg/m2 (grade 2, cycle 22).
3.3 Other safety outcomes
All patients experienced at least one AE. AEs occurring in more than
15% of patients overall are summarized in Table 2. In the overall study
population, the most frequent grade 3/4 AEs were febrile neutrope-
nia, thrombocytopenia, neutropenia (41% each), and anemia (32%).
The most common drug-related AEs of any grade were anemia (41%),
febrile neutropenia (36%), neutropenia (36%), and thrombocytopenia
(36%); these are consistent with volasertib’s knownmyelosuppressive
effects. Seventeen (77%) patients experienced at least one serious AE;
these included 7/12 (58%) patients aged 2 to <12 years and 10/10
(100%) patients aged 12 to<18 years.
Analysis of QTcF changes in relation to plasma concentrations indi-
cated potential concentration-dependent QTcF prolongation in pedi-
atric patients; QTcF prolongation with volasertib has been found to
be due to inhibition of the hERG potassium channel (IC50 2.4 µmol/L).
Themean increase frombaselineQTcF to the end of volasertib infusion
ranged from 36.7 to 40.4 ms in patients aged 2 to <12 years, and from
21.6 to 41.8 ms in patients aged 12 to <18 years. After the end of the
infusion, the mean QTcF prolongation decreased and reached values
lower than or equaling baseline values 1 day after infusion in patients
aged 12 to <18 years, and in patients aged 2 to <12 years treated at
200 mg/m2. For patients aged 2 to <12 years who received volasertib
≥250 mg/m2, mean QTcF prolongation persisted beyond 24 hours fol-
lowing the end of infusion.
3.4 Efficacy outcomes
Efficacy results byagegroupand tumor typeare summarized inTable3.
Across all the patients treated, the best OR was stable disease (SD).
SD was achieved in five patients with leukemia (2 to <12 years, n =
4/4 [100%]; 12 to <18 years, n = 1/3 [33%]), all of whom had reduced
leukemia blast counts in peripheral blood compared with that at base-
line disease. In addition, two patients with ST (neuroblastoma and
osteosarcoma) achieved SD, both aged12 to<18 years (n=2/7 [29%]).
For the patient with neuroblastoma (age 15 years at study entry), 8.5
years had elapsed between the first diagnosis and study entry, during
which time the patient received three lines of polychemotherapy. For
the patient with osteosarcoma (age 17 years at study entry), the time
between the first diagnosis and study entry was 6.8 years; the patient
had received five lines of polychemotherapy. For both patients, mitotic
spindle inhibitors (vincristin, vindesin, and vinblastin) were among the
previous treatments.
For patients with leukemia with a best OR of SD, EFS and OS were
short in duration (maximum EFS ≤3.2 months, maximum OS ≤7.3
months). Of the two patients with ST who had a best response of SD,
one patient (male, osteosarcoma) had received 28 cycles of volasertib
treatmentwith a PFS of 15.7months andwas alive at data cut-off (cen-
sored OS of 15.9 months). This patient initially received 250 mg/m2;
this was subsequently reduced to 200 mg/m2 due to grade 2 QTcF
prolongation following cycle 22 (recovered within 2 days). The second
patient (male, neuroblastoma) received six cycles of volasertib treat-
ment with a PFS of 5.2 months and was alive at data cut-off (censored
OS of 10.3 months). The patient had been treated with 200 mg/m2
volasertib.
3.5 Volasertib PK parameters
PK data were available for all treated patients. Volasertib geometric
mean plasma concentration-time curves for cycle 1 are displayed by
age group (Figure 1). The profiles were of similar shape for all dose
groups, and volasertib Cmax was generally observed around the end of
the ∼1-h intravenous administration. The t1/2 of volasertib was long,
and lowbut quantifiable plasma concentrations could bemeasured10-
14 days after the first infusion. Moderate to high interindividual vari-
ability was evident. PK parameters for volasertib are summarized in
Table 4. Dose-normalized exposure parameters (AUC, Cmax) tended to
be higher in the age group of 2 to <12 years compared with the 12 to
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TABLE 3 BestOR, EFS/PFS, andOSwith volasertib in patients with
leukemia and ST
Age 2 to
<12 years
Age 12 to
<18 years
Patients with leukemia, n 4 3
Patient with any response
evaluations post baseline, n (%)
4 (100) 3 (100)
Best OR, n (%)
CR 0 0
CRi 0 0
PR 0 0
SD 4 (100)a 1 (33)a
PD 0 2 (67)
Median EFS, months (range) 2.1 (1.0-3.2) 0.9 (0.2-3.1)
MedianOS, months (range) 2.7 (1.7-4.0) 7.3 (0.5-8.7)
Patients with an ST, n 8 7
Patients with any response
evaluations post baseline, n (%)
7 (88) 6 (86)
Best OR, n (%)
CR 0 0
PR 0 0
SD 0 2 (29)b,c
PD 7 (88) 4 (57)
Missing 1 (13) 1 (14)
Median PFS, months (range) 0.7 (0.4-1.0) 1.7 (0.7-15.7)
MedianOS, months (range) 1.9 (0.7-11.9) 3.2 (0.9-15.9)
Abbreviations: CR, complete remission; CRi, complete remission with
incomplete blood count recovery; EFS, event-free survival; OR, overall
response; OS, overall survival; PD, progressive disease; PFS, progression-
free survival; PR, partial response; SD, stable disease; ST, solid tumors.
aIncluding transient reduction of blasts.
bFor up to 28 cycles in a patient with osteosarcoma.
cIncluding transient reduction of tumormarker neuron-specific enolase in a
patient with neuroblastoma.
<18 years age group. CL and Vss were higher in the 12 to <18-year-
old group than in the 2 to <12-year-old group. No difference in mean
residence time was apparent between age groups; however, t1/2 was
longer in the younger than in the older age group. There was no appar-
ent deviation from dose proportionality, as dose-normalized AUC0-∞
was comparable between doses in the two age groups.
4 DISCUSSION
In this open-label, noncontrolled, phase I dose-escalation study in pedi-
atric patients with acute leukemia or ST without suitable alternative
treatment options, the MTD of volasertib was 200 mg/m2 in patients
aged 12 to <18 years. In patients aged 2 to <12 years, the pediatric
dose of volasertib for use in further development was 300 mg/m2
(MTD not reached). Volasertib’s safety profile was similar in both
groups, and AEs were as expected given volasertib’s mechanism of
action and the safety outcomes reported in adult studies. Themost fre-
quently observed grade ≥3 AEs were either hematological (thrombo-
cytopenia, neutropenia, and anemia) or resulted from myelosuppres-
sion (febrile neutropenia).
In patients with heavily pretreated relapsed/refractory malignan-
cies, we observed preliminary evidence of limited antitumor and
antileukemic activity, with SD reported as the best response in five
patients with leukemia and two patients with ST. No specific rea-
sons could be identified as to why the two patients with ST achieved
disease stabilization and consequently received extended volasertib
treatment. For both, the time between initial diagnosis and enrolment
was prolonged, which may indicate that their particular tumors were
only slowly proliferating. The observation that volasertib had limited
activity in the remaining patients is consistent with findings in adults
showing only limited antileukemic activity with volasertib monother-
apy at doses less than or equal to 350mg.23,30 The populations of both
age groups were heterogeneous; together with the small sample size,
this meant the analysis of EFS/PFS andOSwas not possible.
F IGURE 1 Geometric mean drug plasma concentration-time profiles of volasertib after intravenous infusion of 200, 250, and 300mg/m2 of
volasertib in cycle 1, by age group—(A) linear scale, (B) semi-log scale
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TABLE 4 Summary of PK parameters of volasertib after the first infusion
Pooled Age 2 to<12 years Age 12 to<18 years
Parametera
Dose
group,
mg/m2 n
gMean
(gCV, %) n
gMean
(gCV, %) n
gMean
(gCV, %)
AUC0-∞,norm, ng × h/mL/mg 200 9 32.4 (31.6) 3 41.7 (40.1) 6 28.6 (19.0)
250 7 31.6 (70.3) 3 51.2 (69.8) 4 22.1 (37.9)
300 6 36.4 (28.2) 6 36.4 (28.2) 0 –
Cmax,norm, ng/mL/mg 200 9 3.19 (62.2) 3 5.34 (22.0) 6 2.46 (54.9)
250 7 4.47 (149) 3 9.71 (128) 4 2.50 (94.6)
300 6 3.60 (35.1) 6 3.60 (35.1) 0 –
t1/2, h 200 9 85.6 (29.0) 3 102 (28.6) 6 78.6 (27.3)
250 7 77.6 (53.8) 3 130 (14.1) 4 52.7 (17.7)
300 6 54.8 (27.2) 6 54.8 (27.2) 0 –
CL, mL/min 200 9 514 (31.6) 3 400 (40.1) 6 583 (19.0)
250 7 527 (70.3) 3 326 (69.8) 4 755 (37.9)
300 6 458 (28.2) 6 458 (28.2) 0 –
Vss, L 200 9 1820 (50.5) 3 1270 (4.0) 6 2180 (52.9)
250 7 1710 (116) 3 1170 (103) 4 2270 (128)
300 6 855 (54.6) 6 855 (54.6) 0 –
MRT, h 200 9 59.0 (47.7) 3 53.1 (35.7) 6 62.3 (55.7)
250 7 54.1 (70.8) 3 59.9 (44.8) 4 50.1 (98.0)
300 6 31.1 (29.4) 6 31.1 (29.4) 0 –
Abbreviations: AUC0-∞,norm, dose-normalized area under the curve from time0 extrapolated to infinity; Cmax,norm, dose-normalizedmaximumplasma concen-
tration; CL, plasma clearance rate; gCV, geometric coefficient of variation; gMean, geometric mean; MRT, mean residence time; PK, pharmacokinetics; t1/2,
plasma half-life; Vss, volume of distribution at steady state.
aThe trough concentration of volasertib (predose concentration in plasma immediately before administration of the second dose [Cpre,2]) was not evaluated,
as most patients had only received one cycle of volasertib treatment.
Albeit based on a limited patient population, PK data were com-
parable with data from clinical studies in adults, in which volasertib
demonstrated dose proportionality, moderate plasma clearance, a high
volume of distribution, and a long t1/2.
19,30 Given the limited num-
ber of subjects and the moderate-to-high PK variability, it is not pos-
sible to draw robust conclusions about age-related differences in
these patients. However, it appears that the younger age group had
higher systemic exposure and higher peak plasma concentrations of
volasertib than the older age group did, whereas CL and Vss were
higher in the 12 to <18-year-old group than in the 2 to <12-year-old
group. There was no difference in mean residence time between age
groups, but t1/2 appeared to be longer in the younger group than in
the older group. Given the PK properties of volasertib, t1/2 derived
from noncompartmental analysis may not directly reflect elimination,
but insteadmay be related to redistribution from deep compartments.
Volasertib distributes to lysosomes, and is a cationic amphiphilic com-
pound with a tendency to accumulate in acidic organelles31; this may
explain the large observed Vss. A more detailed assessment and devel-
opment of PK models is required to characterize the potential age
dependence of clearance or volume of distribution in children. The fact
that dose-normalized data were similar between age groups indicates
that exposurewas proportional to dosewithin the range administered.
No direct relationship between plasma exposure and toxicity could be
identified. The small sample size and the heterogeneity of the patients
enrolled may explain why complications related to myelosuppression
were observed in the older age group only. However, the incidence of
cytopenia resulting from themyelosuppressive effect of volasertibwas
similar between age groups.
Of note, this study did not enroll patients <2 years of age, so
the results may not apply to this group. Neutrophil and platelet
counts decreased after administration of volasertib compared with
pretreatment values, although no meaningful interpretation of the
correlation with PK parameters was possible due to the small
sample size. Correlation analyses suggested a positive relationship
between volasertib plasma concentrations and changes in QTcF in
pediatric patients, in agreement with previous observations in adult
patients.19,22,32
Clinical development of volasertibwasdiscontinued in2017 follow-
ing a strategic decision made by the sponsor. Nevertheless, given that
high expression of PLK1has been correlatedwith poor prognosis,7 and
its inhibition causes cell-cycle arrest and apoptosis in tumor cells,6,8–14
PLK1 remains an attractive target for anticancer drugs. The results
from this trial provide further insight into the efficacy and pharma-
codynamics of volasertib in different pediatric tumor types, which
may help to identify patients likely to respond to alternative PLK1
inhibitors. Our findings confirm that PLK1 inhibition can mediate
antitumor effects, albeit modest, in pediatric patients. Further inves-
tigation in studies on other PLK inhibitors may be beneficial to
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investigate combination treatments based on preclinical evidence of
synergy,33–35 and to identify potential biomarkers predictive of clinical
activity.
In conclusion, the MTD of volasertib when given every 14 days
was 200 mg/m2 in patients aged 12 to <18 years, while for patients
aged 2 to <12 years, the pediatric dose for further development was
300 mg/m2. The pediatric doses described here are in the same range
or higher than the doses of single-agent volasertib recommended for
adults. Safety, PK, and pharmacodynamic findings were as expected,
and volasertib showed limited antitumor/antileukemic activity in this
heavily pretreated pediatric population. Although the clinical develop-
ment of volasertib has been terminated, these results may be relevant
to the development of other PLK inhibitors for pediatric patients with
cancer.
ACKNOWLEDGMENTS
We thank all participating patients and their families, and the nursing
and medical staff, especially Dr Maria Pia Cefalo, Dr Giuseppe Maria
Milano, Dr Benoit Brethon, Dr Marie-Dominique Tabone, Dr Bram De
Wilde, Dr Nadège Corradini, Cécile Giraud, Dr Isabelle Aerts, Dr Irene
Jimenez, and AnneMaclou.
Medical writing assistance, supported financially by Boehringer
Ingelheim, was provided by Nabeela Farooq of GeoMed, an Ashfield
company, part of UDG Healthcare plc, during the preparation of this
manuscript. The authors were fully responsible for all content and edi-
torial decisions,were involved at all stages ofmanuscript development,
and have approved the final version.
CONFLICT OF INTEREST
Rene Fuertig, Kathrin Riemann, and Tillmann Taube are employees
of Boehringer Ingelheim. Matthias Fischer received honoraria from
Novartis. The remaining authors have nothing to declare.
DATA SHARING
To ensure independent interpretation of clinical study results,
Boehringer Ingelheim grants all external authors access to all relevant
material, including participant-level clinical study data, and relevant
material as needed by them to fulfill their role and obligations as
authors under ICMJE criteria.
Furthermore, clinical study documents (eg, study report, study pro-
tocol, statistical analysis plan) and participant clinical study data are
available to be shared after publication of the primary manuscript
in a peer-reviewed journal and if regulatory activities are complete
and other criteria met per the BI Policy on Transparency and Pub-
lication of Clinical Study Data (https://trials.boehringer-ingelheim.
com/transparency_policy.html).
Prior to providing access, documents will be examined and, if nec-
essary, redacted and the data will be de-identified, to protect the
personal data of study participants and personnel, and to respect the
boundaries of the informed consent of the study participants.
Clinical study reports and related clinical documents can be
requested via the following link: https://trials.boehringer-ingelheim.
com/trial_results/clinical_submission_documents.html. All such reque-
sts will be governed by a document sharing agreement.
Bona fide, qualified scientific and medical researchers may request
access to de-identified, analyzable participant clinical study data with
corresponding documentation describing the structure and content of
the datasets. Upon approval, and governed by a data sharing agree-
ment, data are shared in a secured data-access system for a limited
period of 1 year, whichmay be extended upon request.
Researchers should use https://clinicalstudydatarequest.com to
request access to study data.
ORCID
Didier Frappaz https://orcid.org/0000-0002-3684-9909
Dirk Reinhardt https://orcid.org/0000-0001-6300-3434
REFERENCES
1. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and ado-
lescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83-103.
2. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: interna-
tional progress and future directions. Leukemia. 2005;19(12):2025-
2029.
3. National Cancer Institute. Cancer in children and adolescents fact
sheet. 2017. https://www.cancer.gov/types/childhood-cancers/child-
adolescent-cancers-fact-sheet#r1 [Accessed December 18, 2018].
4. Hunger SP, Lu X, Devidas M, et al. Improved survival for children
and adolescents with acute lymphoblastic leukemia between 1990
and 2005: a report from the Children’s Oncology Group. J Clin Oncol.
2012;30(14):1663-1669.
5. Takaki T, TrenzK, CostanzoV, PetronczkiM. Polo-like kinase 1 reaches
beyondmitosis-cytokinesis, DNAdamage response, and development.
Curr Opin Cell Biol. 2008;20(6):650-660.
6. SmithMR,WilsonML, Hamanaka R, et al. Malignant transformation of
mammalian cells initiated by constitutive expression of the Polo-like
kinase. Biochem Biophys Res Commun. 1997;234(2):397-405.
7. LiuZ, SunQ,WangX. PLK1, a potential target for cancer therapy.Transl
Oncol. 2017;10(1):22-32.
8. Ackermann S, Goeser F, Schulte JH, et al. Polo-like kinase 1 is
a therapeutic target in high-risk neuroblastoma. Clin Cancer Res.
2011;17(4):731-741.
9. Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y. Small
interfering RNA-mediated Polo-like kinase 1 depletion preferentially
reduces the survival of p53-defective, oncogenic transformedcells and
inhibits tumor growth in animals. Cancer Res. 2005;65(7):2698-2704.
10. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic
therapies: can we improve on tubulin agents? Nat Rev Cancer.
2007;7(2):107-117.
11. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive
severe Plk1 depletion.Mol Cell Biol. 2006;26(6):2093-2108.
12. Renner AG, Dos Santos C, Recher C, et al. Polo-like kinase 1 is overex-
pressed in acutemyeloid leukemia and its inhibition preferentially tar-
gets the proliferation of leukemic cells. Blood. 2009;114(3):659-662.
13. SteegmaierM,HoffmannM, BaumA, et al. BI 2536, a potent and selec-
tive inhibitor of Polo-like kinase 1, inhibits tumor growth in vivo. Curr
Biol. 2007;17(4):316-322.
14. Xie S, Xie B, Lee MY, Dai W. Regulation of cell cycle checkpoints by
Polo-like kinases.Oncogene. 2005;24(2):277-286.
10 of 10 DOZ ET AL
15. Schöffski P. Polo-like kinase (PLK) inhibitors in preclinical and early
clinical development in oncology.Oncologist. 2009;14(6):559-570.
16. Rudolph D, Steegmaier M, Hoffmann M, et al. BI 6727, a Polo-like
kinase inhibitor with improved pharmacokinetic profile and broad
antitumor activity. Clin Cancer Res. 2009;15(9):3094-3102.
17. Gjertsen BT, Schöffski P. Discovery and development of the Polo-like
kinase inhibitor volasertib in cancer therapy. Leukemia. 2015;29(1):11-
19.
18. Ottmann OG, Muller-Tidow C, Kramer A, et al. Phase I dose-
escalation trial investigating volasertib as monotherapy or in com-
bination with cytarabine in patients with relapsed/refractory acute
myeloid leukaemia. Br J Haematol. 2019;184:1018-1021.
19. Schöffski P, Awada A, Dumez H, et al. A phase I, dose-escalation study
of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients
with advanced solid tumours. Eur J Cancer. 2012;48(2):179-186.
20. Pujade-Lauraine E, Selle F, Weber B, et al. Volasertib versus chem-
otherapy in platinum-resistant or -refractory ovarian cancer: a ran-
domized phase II Groupe des Investigateurs Nationaux pour l’Etude
des Cancers de l’Ovaire study. J Clin Oncol. 2016;34(7):706-713.
21. Ellis PM, Leighl NB, Hirsh V, et al. A randomized, open-label phase II
trial of volasertib as monotherapy and in combination with standard-
dose pemetrexed comparedwith pemetrexedmonotherapy in second-
line treatment for non-small-cell lung cancer. Clin Lung Cancer.
2015;16(6):457-465.
22. Stadler WM, Vaughn DJ, Sonpavde G, et al. An open-label, single-arm,
phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in
patients with locally advanced or metastatic urothelial cancer. Cancer.
2014;120(7):976-982.
23. Döhner H, LübbertM, FiedlerW, et al. Randomized, phase 2 trial com-
paring low-dose cytarabinewith orwithout volasertib in AML patients
not suitable for intensive induction therapy. Blood. 2014;124(9):1426-
1433.
24. Gorlick R, Kolb EA, Keir ST, et al. Initial testing (stage 1) of the Polo-
like kinase inhibitor volasertib (BI 6727), by the Pediatric Preclinical
Testing Program. Pediatr Blood Cancer. 2014;61(1):158-164.
25. Harris PS, Venkataraman S, Alimova I, et al. Polo-like kinase 1 (PLK1)
inhibition suppresses cell growth and enhances radiation sensitivity in
medulloblastoma cells. BMCCancer. 2012;12:80.
26. Lanvers-Kaminsky C, Abbou S, udigeos-Dubus E, et al. Anti-tumor
activity of the PLK inhibitor volasertib (BI 6727) and the aurora
kinase inhibitor BI 811283 in pediatric malignancies. Eur J Cancer.
2012;48(Suppl 6):78.
27. Smith M, Keir S, Maris J, et al. Pediatric Preclinical Testing Program
(PPTP) evaluation of volasertib (BI 6727), a Polo-like kinase (PLK)
inhibitor. Cancer Res. 2012;72(8):LB-317.
28. Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis
and management of acute myeloid leukemia in children and adoles-
cents: recommendations from an international expert panel. Blood.
2012;120(16):3187-3205.
29. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation
criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J
Cancer. 2009;45(2):228-247.
30. Bug G, Müller-Tidow C, Schlenk RF, et al. Phase I/II study of volasertib
(BI 6727), an intravenous Polo-like kinase (PLK) inhibitor, in patients
with acute myeloid leukemia (AML): updated results of the dose find-
ing phase I part for volasertib in combinationwith low-dose cytarabine
(LD-Ara-C) and as monotherapy in relapsed/refractory AML. Blood.
2011;118(21):1549.
31. Solans BP, Fleury A, Freiwald M, Fritsch H, Haug K, Troconiz IF. Pop-
ulation pharmacokinetics of volasertib administered in patients with
acute myeloid leukaemia as a single agent or in combination with
cytarabine. Clin Pharmacokinet. 2018;57(3):379-392.
32. Kobayashi Y, Yamauchi T, Kiyoi H, et al. Phase I trial of volasertib,
a Polo-like kinase inhibitor, in Japanese patients with acute myeloid
leukemia. Cancer Sci. 2015;106(11):1590-1595.
33. Abbou S, Lanvers-Kaminsky C, Daudigeos-Dubus E, et al. Polo-like
kinase inhibitor volasertib exhibits antitumor activity and synergywith
vincristine in pediatric malignancies. Anticancer Res. 2016;36(2):599-
609.
34. Weiss LM, Hugle M, Romero S, Fulda S. Synergistic induction of apop-
tosis by a Polo-like kinase 1 inhibitor and microtubule-interfering
drugs in Ewing sarcoma cells. Int J Cancer. 2016;138(2):497-506.
35. Hugle M, Belz K, Fulda S. Identification of synthetic lethality of
PLK1 inhibition and microtubule-destabilizing drugs. Cell Death Differ.
2015;22(12):1946-1956.
How to cite this article: Doz F, Locatelli F, Baruchel A, et al.
Phase I dose-escalation study of volasertib in pediatric patients
with acute leukemia or advanced solid tumors. Pediatr Blood
Cancer. 2019;e27900. https://doi.org/10.1002/pbc.27900
